Response to immunotherapy plus anti-angiogenic agent combination challenges hepatocellular carcinoma prognostic
1Department of Gastroenterology and Hepatology, Hôpital Saint-Joseph, Marseille, France.
Hepatology Communications
|July 12, 2022
Abstract:
This new UHPI score identifies three groups with different prognosis, but with no clear therapeutic guidance. Moreover, this model's predictive ability is now challenged in the era of combination therapies where durable responses are more commonly observed, and where response criteria remain to be defined.
More Related Videos
Related Concept Videos
01:27Tumor Immunotherapy
652
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
652
02:50Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K